Product IntroductionBioactivity英文名:
J22352描述: J22352, a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM, enhances anticancer effects in glioblastoma by promoting HDAC6 degradation. It does so by inhibiting autophagy and stimulating the antitumor immune response, further restoring host antitumor activity through the reduction of PD-L1's immunosuppressive activity.
体外活性: J22352 (10 μM; 24 hours) shows a dose-dependent decrease in HDAC6 protein abundance. J22352 (0.1-20 μM; 72 hours) decreases U87MG cell viability in a dose-dependent manner.
体内活性: J22352 is well tolerated in mice.J22352 (10?mg/kg; given i.p. per day for 14 days in male nude mice) results in a >80% tumor growth inhibition (TGI) rate.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 125 mg/mL (300.89 mM)
关键字:
J-22352 |
J22352 |
J 22352相关产品:
Centrolobol |
Fenbufen |
Myricanone |
Ginsenoside Rh2 |
JC2-11 |
Ossirene |
Ivachtin |
Nivalenol |
Biotin-VAD-FMK |
MDK83190